Aethlon Medical, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2022, with comparison to the year ended March 31, 2021. Although the request metadata refers to 2021 Q4, this filing reports full fiscal-year results, not a standalone quarter. Aethlon Medical (Nasdaq: AEMD) is a clinical-stage medical technology company; it reported no commercial product sales.
Business context
The company is developing the Hemopurifier, an investigational device intended to remove tumor-derived exosomes and certain viruses from the blood. The FDA has granted it Breakthrough Device designation for specified cancer and life-threatening viral-disease indications; this designation is not marketing approval. Aethlon also majority-owns Exosome Sciences, Inc. (ESI), which had no revenue.
- The head-and-neck cancer feasibility study with pembrolizumab was designed for 10–12 patients; two had been treated, and recruitment was ongoing.
- The U.S. COVID-19 feasibility study was designed for up to 40 patients at up to 20 centers. The filing reports nine U.S. hospitals activated and screening patients; the first patient completed the treatment phase in June 2022, after fiscal year-end.
- A COVID-19 trial site in India was open and screening patients. The filing describes prior emergency-use cases, but does not provide a consistent total across all sections.
Financial results and liquidity
| Metric | FY ended Mar. 31, 2022 | FY ended Mar. 31, 2021 |
|---|---|---|
| Revenue, entirely government contracts and grants | $294,165 | $659,104 |
| Operating expenses | $10,715,050 | $8,550,603 |
| Operating loss / net loss before noncontrolling interests | $(10,420,885) | $(7,891,499) |
| Net loss attributable to common stockholders | $(10,416,091) | $(7,886,709) |
| Basic and diluted loss per share | $(0.71) | $(0.65) |
| Cash used in operating activities | $(9,767,157) | $(6,764,940) |
| Cash provided by financing activities | $17,367,974 | $7,128,342 |
- Revenue fell about 55% year over year, while operating expenses rose about 25% and net loss before noncontrolling interests increased about 32%.
- At March 31, 2022, cash was $17.07 million, working capital was $16.33 million, and total assets were $19.42 million. Total liabilities were $2.43 million, including $729,410 in lease liabilities; the filing reports no convertible notes outstanding.
- Financing included $4.95 million net proceeds from the 2021 at-the-market (ATM) program, $11.66 million net proceeds from a registered direct offering, and proceeds from warrant and option exercises. The company reported 15.42 million common shares outstanding at fiscal year-end.
- Management stated that cash as of March 31, 2022 was expected to fund operations for at least 12 months from the filing’s issuance date. It also expects continued losses, negative cash flows and a need for additional capital.
Material changes, outlook and risks
- Lower revenue reflected the absence of the $188,444 breast-cancer grant revenue recognized in FY2021 and lower recognized revenue from the Phase II melanoma contract. The latter’s FY2022 revenue included $229,698 previously deferred after milestone shortfalls; invoices for later contract periods were deferred because certain milestones were not met.
- Higher expenses included increased payroll and general and administrative costs. Management cited increased clinical-trial costs, rent and insurance; research and development expense was approximately $2.34 million, up from $2.07 million.
- The Phase II NCI melanoma contract, valued at $1.86 million, was scheduled to run through September 15, 2022. The company said it might not obtain further government contracts after that award.
- Aethlon’s key risks include its dependence on external financing and potential dilution; clinical enrollment, safety and efficacy uncertainty; the need for FDA PMA approval; competition; limited manufacturing capacity and reliance on key suppliers; and possible COVID-19, inflation and market-related delays or funding constraints. Breakthrough designation does not assure approval or faster development.
- The company entered leases for new office and laboratory space and a planned manufacturing facility; occupancy of the manufacturing space was anticipated in calendar Q3 2022. It reported no pending legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Current cash, cash burn and financing needs against the company’s stated 12-month runway; also track subsequent ATM share sales and dilution. The filing reports $448,760 of net ATM proceeds in June 2022.
- Enrollment, treatment completion, safety findings and outcomes in the cancer and COVID-19 studies, and whether timelines or protocols have changed since the filing.
- Milestone completion, deferred revenue and any replacement government or grant funding after the Phase II contract’s scheduled September 2022 end.
- Manufacturing readiness, supplier qualification and the status and cost of the planned manufacturing facility, alongside the regulatory steps required for any commercial approval.